ReviewAJR. American journal of roentgenology2026
Opportunistic Screening on Chest CT, From the
Review in AJR. American journal of roentgenology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Observational
- CT-Derived Pectoralis Muscle Measurements and All-Cause Mortality in COPD.Diagnostics (Basel, Switzerland) · 2026Article
- The role of AI assistance in the evaluation of unenhanced chest CT scans in an emergency setting.Polish journal of radiology · 2026Article
- A Vision Toward Risk-Stratified Postoperative Surveillance for Lung Cancer: Harnessing CT and AI.Journal of the American College of Radiology : JACR · 2025Article
- Opportunistic screening of osteoporosis in lung transplant recipients: diagnostic value of pre-transplant thoracic CT using vertebral Hounsfield units.Journal of orthopaedic surgery and research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
The increase in chest CT volumes affords radiologists the opportunity to systematically assess imaging biomarkers, including coronary and thoracic arterial calcification, emphysema, airway dysanapsis, adipose tissue in various compartments, skeletal muscle (in terms of both quantity and quality), and vertebral body bone attenuation (as a measure of bone mineral density), extending from the T1 through T12 vertebral body levels. These biomarkers represent a spectrum of disease-induced changes or increases in the risk of developing disease. This Special Series Review provides an overview of these established and emerging imaging biomarkers on chest CT scans, aiming to serve as a reference for practicing radiologists. We discuss the importance of imaging biomarkers for patient care; highlight recent developments; present approaches for interpretation and integration into clinical workflows, with attention given to the role of reference values; consider challenges in serial assessment resulting from variations in technical parameters; describe the incorporation of the biomarkers into societal guidelines; and summarize FDA-approved artificial intelligence tools to aid evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.